Circle Pharma Stock

circlepharma.comHealthcare / BioTech & PharmaFounded: 2012

Circle Pharma is a biotechnology company which offers macrocycle therapeutics to patients with diseases and cancers. This company was founded by Matthew Jacobson Ph.D and Scott Lokey Ph.D in 2012 and is headquartered in South San Francisco, CA. Circle Pharma’s proprietary MXMO™ platform is designed to target intracellular protein-protein interactions (PPIs), combining drug design with synthetic chemistry advancements to create drug candidates that are intended to be cell-permeable and orally bioavailable for oncology treatments.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Circle Pharma, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation
Private Market Pricing DetailsValuation & Financings

Enterprise Value

Powered by Forge Data

Access Circle Pharma’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Animation displayed is not current and securities are shown for illustrative purposes only.

Circle Pharma Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Circle Pharma Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Circle Pharma investors also invested in these private companies

Leadership & Board

Leadership

Matthew Jacobson Ph.D
Co-Founder & Chief Scientific Officer
Edward Garmey MD
Chief Medical Officer
Paul Park
Chief Business Officer
David Earp JD, Ph.D
President & Chief Executive Officer
Jim Aggen Ph.D
Vice President of Medicinal Chemistry
Pablo Garcia Ph.D
Vice President of Biology Research
Michael Cox
Senior Vice President & Head of Early Development
Constantine Kreatsoulas Ph.D
Vice President & Head of Research, Research Informatics, and Computational Chemistry

Board

Thilo Schroeder Ph.D
Nextech Invest
James Evangelista
The Column Group
John Josey Ph.D
The Column Group

Circle Pharma stock FAQs

plusminus

Can you buy Circle Pharma stock?

As Circle Pharma is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Circle Pharma, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Circle Pharma stock?

To invest in a private company like Circle Pharma through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Circle Pharma stock?

Yes, you may sell the Circle Pharma stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Circle Pharma stock?

If you hold private company shares of Circle Pharma – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Circle Pharma on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Circle Pharma a public company?

No, Circle Pharma is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Circle Pharma’s stock price?

Circle Pharma is a privately held company and therefore does not have a public stock price. However, you may access Circle Pharma private market stock price with Forge Data.
plusminus

What is Circle Pharma’s stock ticker symbol?

Circle Pharma does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Circle Pharma’s news and media highlights

Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycle therapies, today announced that it presented a digital poster at the 2024 World Conference on Lung Cancer. CID-078, Circle Pharma’s first-and-only-in-class cyclin A/B RxL inhibitor, demonstrated single-agent tumor regressions in both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) preclinical models.
Circle Pharma, a San Francisco, CA-based clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, raised $90M in Series D funding. The round was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital. The company intends to use the funds to fund the clinical development of CID-078, its cyclin A/B RxL inhibitor, and to support the development of its portfolio of discovery programs built with its MXMO macrocycle platform.
Updated on: Oct 10, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price™ may rely on a very limited number of inputs in its calculation. Forge Price™ is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price™, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price™. Forge Price™ is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price™ is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price™ for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.